Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis

Kashii, Masafumi; Kamatani, Takashi; Nagayama, Yoshio; Miyama, Akira; Tsuboi, Hideki; Ebina, Kosuke

doi:https://doi.org/10.1007/s00198-022-06642-1

Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis

Kashii, Masafumi; Kamatani, Takashi; Nagayama, Yoshio et al.

Osteoporosis International, 2023, 34(3), 563-572

Number of Access:496（2025-09-03 11:38 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/93245

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
OsteoporosisInt_34_3_563	pdf	None	2.04 MB	73	2023.12.07

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis
Creator	NRID 1000000576910 1000000576910 CreatorName Kashii, Masafumi
	CreatorName Kamatani, Takashi
	CreatorName Nagayama, Yoshio
	CreatorName Miyama, Akira
	CreatorName Tsuboi, Hideki
	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 CreatorName Ebina, Kosuke
Subject	Bone mineral density
	Postmenopausal osteoporosis
	Responder analysis
	Romosozumab
	Type I procollagen N-terminal propeptide
Description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00198-022-06642-1
Description	Kashii M., Kamatani T., Nagayama Y., et al. Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis. Osteoporosis International 34, 563 (2023)
Abstract	Summary: Baseline serum PINP value was significantly and independently associated with the increased bone mineral density (≥ 3%) in both total hip and femoral necks by 12 months of romosozumab treatment in patients with treatment-naive postmenopausal osteoporosis. Purpose: Some patients fail to obtain a sufficiently increased hip bone mineral density (BMD) by romosozumab (ROMO) treatment. This study aimed to investigate the prognostic factor for increased hip BMD with ROMO in patients with treatment-naive postmenopausal osteoporosis. Methods: This prospective, observational, and multicenter study included patients (n = 63: mean age, 72.6 years; T-scores of the lumbar spine [LS], − 3.3; total hip [TH], − 2.6; femoral neck [FN], − 3.3; serum type I procollagen N-terminal propeptide [PINP], 68.5 µg/L) treated by ROMO for 12 months. BMD and serum bone turnover markers were evaluated at each time point. A responder analysis was performed to assess the patient percentage, and both univariate and multivariate analyses were performed to investigate the factors associated with clinically significant increased BMD (≥ 3%) in both TH and FN. Results: Percentage changes of BMD from baseline in the LS, TH, and FN areas were 17.5%, 4.9%, and 4.3%, respectively. In LS, 96.8% of patients achieved ≥ 6% increased LS-BMD, although 57.1% could not achieve ≥ 3% increased BMD in either TH or FN. Multiple regression analysis revealed that only the baseline PINP value was significantly and independently associated with ≥ 3% increased BMD in both TH and FN (p = 0.019, 95% confidence interval = 1.006–1.054). The optimal cut-off PINP value was 53.7 µg/L with 54.3% sensitivity and 92.3% specificity (area under the curve = 0.752). Conclusions: In a real-world setting, baseline PINP value was associated with the increased BMD of TH and FN by ROMO treatment in treatment-naive patients.
Publisher	Springer Science and Business Media Deutschland GmbH
Source Title	Osteoporosis International
Volume (Issue)	34(3)
Page	563-572
Date of Issued	2023-03-01
Language	English
Handle URL	https://hdl.handle.net/11094/93245
PISSN	0937941X
eISSN	14332965
Relation.isVersionOf	DOI (Publisher Version) https://doi.org/10.1007/s00198-022-06642-1
Access Rights	open access
CopyRight	© 2023, International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation.
oaire:version	Accepted Manuscript
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Osteoporosis International. 2023, 34(3), p. 563-572
DC.title	Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis
DC.creator	Kashii, Masafumi
	Kamatani, Takashi
	Nagayama, Yoshio
	Miyama, Akira
	Tsuboi, Hideki
	Ebina, Kosuke
DC.publisher	Springer Science and Business Media Deutschland GmbH
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2023-03-01
DC.identifier	https://doi.org/10.1007/s00198-022-06642-1
DC.subject	Bone mineral density
	Postmenopausal osteoporosis
	Responder analysis
	Romosozumab
	Type I procollagen N-terminal propeptide
DC.description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00198-022-06642-1
DC.description	Kashii M., Kamatani T., Nagayama Y., et al. Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis. Osteoporosis International 34, 563 (2023)
DCTERMS.abstract	Summary: Baseline serum PINP value was significantly and independently associated with the increased bone mineral density (≥ 3%) in both total hip and femoral necks by 12 months of romosozumab treatment in patients with treatment-naive postmenopausal osteoporosis. Purpose: Some patients fail to obtain a sufficiently increased hip bone mineral density (BMD) by romosozumab (ROMO) treatment. This study aimed to investigate the prognostic factor for increased hip BMD with ROMO in patients with treatment-naive postmenopausal osteoporosis. Methods: This prospective, observational, and multicenter study included patients (n = 63: mean age, 72.6 years; T-scores of the lumbar spine [LS], − 3.3; total hip [TH], − 2.6; femoral neck [FN], − 3.3; serum type I procollagen N-terminal propeptide [PINP], 68.5 µg/L) treated by ROMO for 12 months. BMD and serum bone turnover markers were evaluated at each time point. A responder analysis was performed to assess the patient percentage, and both univariate and multivariate analyses were performed to investigate the factors associated with clinically significant increased BMD (≥ 3%) in both TH and FN. Results: Percentage changes of BMD from baseline in the LS, TH, and FN areas were 17.5%, 4.9%, and 4.3%, respectively. In LS, 96.8% of patients achieved ≥ 6% increased LS-BMD, although 57.1% could not achieve ≥ 3% increased BMD in either TH or FN. Multiple regression analysis revealed that only the baseline PINP value was significantly and independently associated with ≥ 3% increased BMD in both TH and FN (p = 0.019, 95% confidence interval = 1.006–1.054). The optimal cut-off PINP value was 53.7 µg/L with 54.3% sensitivity and 92.3% specificity (area under the curve = 0.752). Conclusions: In a real-world setting, baseline PINP value was associated with the increased BMD of TH and FN by ROMO treatment in treatment-naive patients.
DC.rights	© 2023, International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation.
DC.format	93245
citation_title	Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis
citation_author	Kashii, Masafumi
	Kamatani, Takashi
	Nagayama, Yoshio
	Miyama, Akira
	Tsuboi, Hideki
	Ebina, Kosuke
citation_publisher	Springer Science and Business Media Deutschland GmbH
citation_language	English
citation_date	2023-03-01
citation_journal_title	Osteoporosis International
citation_volume	34
citation_issue	3
citation_firstpage	563
citation_lastpage	572
citation_doi	https://doi.org/10.1007/s00198-022-06642-1
citation_public_url	https://hdl.handle.net/11094/93245

Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis

Link to primary information

Item Information

Show details